BDBM603951 3-Fluoropropyl 2-ethyl-2-{[5-(3-fluoroazetidin-1-yl)-6-{[(1R,2R)-2-(hydroxymethyl)cyclopropyl]methoxy}pyridin-2-yl]formamido}butanoate or 3-fluoropropyl 2-ethyl-2-{[5-(3-fluoroazetidin-1-yl)-6-{[(1S,2S)-2-(hydroxymethyl)cyclopropyl]methoxy}pyridin-2-yl]formamido}butanoate::US11655243, Example 29

SMILES CCC(CC)(NC(=O)c1ccc(N2CC(F)C2)c(OC[C@@H]2C[C@H]2CO)n1)C(=O)OCCCF

InChI Key InChIKey=IAZFSRPHJBIPJK-UHFFFAOYSA-N

Data  1 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 603951   

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603951(US11655243, Example 29 | 3-Fluoropropyl 2-ethyl-2-...)
Affinity DataKi:  10.9nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent